Initial, independent review of study data from the Selenium and Vitamin E Cancer Prevention Trial (SELECT) shows that selenium and vitamin E supplements, taken either alone or together, did not prevent prostate cancer.

Popular cholesterol-busting drugs — statins — appear to lower men’s PSA values along with their cholesterol levels, according to researchers. But whether the drugs prevent prostate cancer growth or just mask it is not known yet.

The government is stopping part of a major study of whether vitamin E and selenium prevent prostate cancer — because the supplements aren’t working and there’s a hint of risk.

The determination of the precise anatomical location of a tumor is the prerequisite for setting optimal parameters for radiation treatment of prostate cancer. This approach guarantees that the ionizing radiation only destroys tumorous cells and does not affect other organs in the vicinity of the prostate. In a cooperative study with Innsbruck Medical University and the East-Vienna Center of Social Medicine, two physicists of Vienna University of Technology (TU), evaluated the mean deviation of radiation parameters for prostate cancers and compared various sources of radiation.

The researchers who first isolated cancer stem cells in adult brain tumors in 2004 have now identified a molecular mechanism that is involved in the development of these cells from which malignant brain tumors may originate. This could offer a target for scientists seeking treatments that would kill malignant brain tumors at their source and prevent them from recurring.

In the last few years, the treatment options for prostate problems have expanded. The German Institute for Quality and Efficiency in Health Care has assessed new treatments and warns that some new surgical techniques are being heavily promoted without first having been adequately evaluated.

Currently, early detection of prostate cancer depends on an abnormal digital rectal examination and an elevated prostate-specific-antigen (PSA) level requiring a prostate biopsy, often associated with anxiety, discomfort, complications, and heavy expenses. Now researchers have developed a test using a new PCa gene-based marker that can be carried out with a urine sample.

The greater the levels of a protein called Insulin-like Growth Factor-1 (IGF-1), the greater the risk of prostate cancer, a new study has found.

To ease the pain of recovery following prostate cancer surgery, physician-scientists have developed an innovative and patient-friendly approach that eliminates the use of a penile urinary catheter. The new patentable technique, used in conjunction with robotic prostatectomy — the surgical removal of the prostate — eliminates the pain and discomfort associated with the standard catheter.

An international study led by researchers at The Institute of Cancer Research will pave the way for a test to be used to better tailor treatments and hopefully extend the survival of men with aggressive forms of metastatic prostate cancer.